Prevalence and trends of hepatitis B and C virus biomarkers in Zimbabwe: comparative analyses of a nation’s blood-donor surveillance data and meta-analyses of population studies
- 14 May 2024
- journal article
- research article
- Published by Taylor & Francis in Infectious Diseases
- Vol. 56 (9) , 759-775
Abstract
BackgroundThe disproportionate burden of viral hepatitis, particularly hepatitis B virus (HBV) is experienced by people living in low-resourced sub-Saharan Africa, where the estimated prevalence is 3-7 times the global average. Therefore to inform policy, we describe the seroprevalence and trends of hepatitis C (HCV) and HBV biomarkers: anti-HCV antibody and hepatitis B surface antigen (HBsAg), respectively, in Zimbabwe.MethodsWe analysed data from 181,248 consecutive blood-donors, examined between January 2015 through December 2018. Additionally, we conducted a comprehensive literature review using PubMed and African Journals Online databases, meta-analysing selected papers from Zimbabwe, published between 1970 and 2020, that met specific criteria.ResultsOverall age-standardized prevalence rate (ASPR) for anti-HCV was 8.67 (95%CI, 0.25-17.09) per 100,000, while that for HBsAg was 2.26 (95%, 1.89-2.63) per 1000 blood-donors, per year. Meta-analysis of 9 studies comprising 220,127 persons tested for anti-HCV revealed ASPR of 0.05% (95% 0%-0.19%) in blood-donors and 1.78% (95%CI, 0.01%-5.55%) in the general population, for an overall pooled ASPR of 0.44 (95%CI, 0.19%-0.76%). 21 studies comprising 291,784 persons tested for HBsAg revealed ASPR of 0.65% (95%CI, 0.31%-1.00%) in blood-donors and 4.31% (95%CI, 1.77%-6.50%) in the general population for an overall pooled ASPR of 4.02% (95%CI, 3.55%-4.48%), after HBV vaccine introduction. HBsAg prevalence was significantly higher before HBV vaccine introductions.ConclusionsThe prevalence of HBV is decreasing, consistent with the introduction of HBV vaccination, while HCV prevalence is increasing in Zimbabwe. This highlights the need for Improved blood-donor screening and more informative biomarker studies, particularly among repeat donors and children.Keywords
This publication has 46 references indexed in Scilit:
- Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targetsThe Lancet Gastroenterology & Hepatology, 2017
- Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030The Lancet Gastroenterology & Hepatology, 2017
- Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex diseaseJournal of Antimicrobial Chemotherapy, 2017
- Molecular epidemiology of co‐infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, ZimbabweJournal of Medical Virology, 2016
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2015
- Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade AssociationEpidemiology and Infection, 2013
- Streptococcus agalactiae colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from ZimbabweEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2010
- Lack of Evidence for Frequent Heterosexual Transmission of Human Herpesvirus 8 in ZimbabweClinical Infectious Diseases, 2009
- Serum ferritin concentrations in Africans with low dietary ironAnnals of Hematology, 2009